Mitesco, Biotech Stock Review

Medtech Incubator True Nature | Mitesco (TNTY) Adds Another Heavy Hitter to Board.

True Nature Holding, Inc. DBA Mitesco, Inc. Adds Distinguished Healthcare Executive to Board of Directors.
video

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below.

https://youtu.be/hnqFdKSG6-A Auris all over the room, even on the ceiling?.

Citius Pharma (CTXR), Fortress Biotech (FBIO) and True Nature (TNTY) Significantly Higher on News.

Fortress Bio (FBIO, $2.42) Up 43%, Citius Pharma (CTXR, $1.15) Up 109% and True Nature Holdings (TNTY, $0.043) Up 117%, Since Adding...
Dyadic

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...

CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).

INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40   Alpha Pro Tech, Ltd. (NYSE: APT)...
Immunomedics, Biotech Stock Review

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.

Our First Newsletter of 2020, We Come out Swinging! Yes, you read it right. Five of our favorite...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...

Citius Pharma (CTXR) Corporate Presentation (Jan 2020).

In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic...
steven boyd, biotech stock review

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

April 2019 Offering On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors...
Citius, Biotech Stock Review

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

PHASE III PROGRESS October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019...

Latest article

Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...